Asensus Surgical (NYSEAMERICAN:ASXC – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01, reports. Asensus Surgical had a negative return on equity of 103.62% and a negative net margin of 1,409.77%. The firm had revenue of $1.09 million for the quarter, compared to analysts’ expectations of $1.50 million.
Asensus Surgical Price Performance
Shares of ASXC stock traded up $0.01 on Friday, hitting $0.23. The stock had a trading volume of 942,626 shares, compared to its average volume of 1,723,563. Asensus Surgical has a one year low of $0.20 and a one year high of $1.18. The company has a market capitalization of $60.56 million, a P/E ratio of -0.68 and a beta of 1.49.
Hedge Funds Weigh In On Asensus Surgical
Large investors have recently bought and sold shares of the business. Millennium Management LLC raised its holdings in Asensus Surgical by 3,552.4% in the second quarter. Millennium Management LLC now owns 5,040,838 shares of the company’s stock worth $2,007,000 after purchasing an additional 4,902,823 shares in the last quarter. Masters Capital Management LLC purchased a new stake in Asensus Surgical during the first quarter valued at approximately $1,213,000. Vanguard Group Inc. lifted its position in Asensus Surgical by 5.3% during the third quarter. Vanguard Group Inc. now owns 11,431,792 shares of the company’s stock valued at $5,130,000 after acquiring an additional 575,904 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in Asensus Surgical in the first quarter valued at approximately $329,000. Finally, AQR Capital Management LLC purchased a new position in Asensus Surgical in the second quarter worth $106,000. Institutional investors own 10.06% of the company’s stock.
Analyst Ratings Changes
Asensus Surgical Company Profile
Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.
- Five stocks we like better than Asensus Surgical
- P/E Ratio Calculation: How to Assess Stocks
- 3 large caps with red hot RSIs with upside
- Basic Materials Stocks Investing
- Johnson Controls International: Nothing but upside for investors
- Growth Stocks: What They Are, Examples and How to Invest
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Asensus Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asensus Surgical and related companies with MarketBeat.com's FREE daily email newsletter.